-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Outperform on Ascendis Pharma, Raises Price Target to $312

Benzinga·09/02/2026 16:55:16
Listen to the news
Oppenheimer analyst Leland Gershell maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $304 to $312.